The $43 billion global oral care market is built on prevention and protection. Toothpaste fights cavities, mouthwash kills bacteria, and whitening strips polish the surface. For Eterna Regeneratives, a 2024 spinout from King’s College London, that entire paradigm is a market opportunity. Its bet is not on fighting decay, but on reversing it. The company’s patented technology uses keratin, a protein derived from human hair and sheep’s wool, to stimulate the natural process of biomimetic mineralisation. The goal is to regrow a functional enamel-like layer on the tooth [PERPLEXITY SONAR PRO BRIEF]. It is a repair job, not a cover-up, and it recently convinced Hoxton Ventures and The Venture Collective to lead a $4 million seed round to bring it to market [PR Newswire, September 2026].
The Biomimetic Wedge
Eterna’s initial wedge is enamel regeneration, a problem dentistry has historically managed, not solved. Current treatments for enamel loss range from fluoride applications to slow demineralisation, to composite fillings and crowns that replace the structure. Eterna’s approach is to supply the biological building blocks,specifically, keratin peptides,that can integrate with the tooth’s surface and guide the deposition of new mineral, effectively rebuilding from the outside in [Health Technology Net, September 2026]. The first planned commercial vehicles are a consumer mouthwash and professional-grade gels for dental clinics, with a potential market launch eyed for early 2027 [Dentistry.co.uk, September 2026]. This positions the company in the lucrative crossover space between consumer packaged goods and professional medical supplies.
Why Hoxton and TVC Wrote the Check
The $4 million seed, reported in September 2026, is a classic early-stage deeptech bet. The investors are backing published academic research translated into a patented, commercially viable material. The foundational science on using sustainable keratin for enamel regeneration appeared in Advanced Healthcare Materials [Particle]. The founding team provides the necessary dual expertise: Dr. Sherif Elsharkawy is a clinical lecturer in prosthodontics at King’s College London, anchoring the dental and clinical credibility, while CEO Khaled Eissa, a PhD candidate at the time of the funding, brings the commercial and operational focus [PERPLEXITY SONAR PRO BRIEF]. For investors, the appeal lies in the platform potential. Enamel repair is the first application, but the underlying keratin-based biomaterial technology is designed for bone regeneration as well, opening a much larger addressable market in orthopedics and reconstructive surgery [PR Newswire, September 2026].
The Road to a Dental Shelf
The path from a lab breakthrough to a product on a supermarket shelf is long, expensive, and fraught with regulatory gates. Eterna’s stated two- to three-year timeline to market is aggressive for a novel biomaterial entering the human body, even topically [Particle]. The company will need to clear significant hurdles that define the real procurement cycle for this category.
- Clinical validation. Peer-reviewed research is a starting point, not a finish line. The company must design and execute robust clinical trials to prove safety and efficacy for enamel regeneration in humans, a process that consumes time and capital.
- Regulatory strategy. Will the initial mouthwash be classified as a cosmetic, a medical device, or a drug? The classification dictates the approval pathway (e.g., FDA, CE Mark), the stringency of evidence required, and the timeline. Navigating this is a core operational risk.
- Manufacturing and supply. Scaling the production of consistent, medical-grade keratin from sustainable sources (human hair, sheep’s wool) presents its own engineering challenges that are separate from the lab science.
- Commercial motion. The dual B2B2C model means building two distinct sales engines: one for convincing dental distributors and clinics of the professional product's value, and another for consumer marketing to explain a complex regenerative benefit in a crowded oral care aisle.
The Realistic Competitive Set
Eterna’s most direct competition does not come from other enamel-regrowth startups, because there effectively are none at this stage. The competitive set is bifurcated. In the professional dental channel, they compete for budget and procedure time against established restorative materials from giants like 3M and Dentsply Sirona, and against the inertia of current dental practice. For the consumer product, the competition is the marketing budgets and shelf space owned by Procter & Gamble (Crest, Oral-B) and Colgate-Palmolive, whose products are built on decades of consumer trust in prevention, not repair. Eterna’s task is to create a new category,regenerative oral care,within these existing landscapes.
The ideal customer profile is telling. For the professional product, it’s the progressive dentist or dental chain looking to offer a minimally invasive, preventive-restorative treatment to patients with early enamel erosion. For the consumer product, it’s the health-conscious, bio-curious consumer already shopping in the premium oral care aisle, willing to pay a significant premium for a product that promises active repair over passive protection. Success hinges on whether Eterna can demonstrate clear, visible results that justify both the dentist's recommendation and the consumer's switch from a $5 tube of toothpaste to a likely $30 bottle of regenerative mouthwash. The $4 million seed is the first check to find out.
Sources
- [PR Newswire, September 2026] Eterna Regeneratives Raises $4m to Pioneer a Platform for Enamel and Bone Regeneration | https://www.prnewswire.com/news-releases/eterna-regeneratives-raises-4m-to-pioneer-a-platform-for-enamel-and-bone-regeneration-302881945.html
- [PERPLEXITY SONAR PRO BRIEF] Company and product overview
- [Dentistry.co.uk, September 2026] Investment moves enamel regeneration closer to market | https://dentistry.co.uk/2026/09/18/3m-investment-moves-enamel-regeneration-technology-closer-to-market/
- [Health Technology Net, September 2026] Eterna Regeneratives Raises $4m to Pioneer a Platform for Enamel and Bone Regeneration | https://healthtechnologynet.com/2026/09/17/eterna-regeneratives-raises-4m-to-pioneer-a-platform-for-enamel-and-bone-regeneration/
- [Particle] Research on biomimetic enamel regeneration using a sustainable protein source (keratin) was published in Advanced Healthcare Materials
- [Sky News, September 2026] Early Deliveroo backer invests in tooth enamel regeneration startup | https://news.sky.com/story/early-deliveroo-backer-invests-in-tooth-enamel-regeneration-startup-13588463